Clevidipine patient counseling information

Revision as of 20:38, 27 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Clevidipine}} {{CMG}}; {{AE}} {{SS}} ==Patient Counseling Information== *Advise patients with underlying hypertension that they require continued follow up f...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Clevidipine
CLEVIPREX® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Clevidipine
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Patient Counseling Information

  • Advise patients with underlying hypertension that they require continued follow up for their medical condition, and, if applicable, encourage patients to continue taking their oral antihypertensive medication(s) as directed.
  • Advise patients to contact a healthcare professional immediately for any of the following signs of a new hypertensive emergency: neurological symptoms, visual changes, or evidence of congestive heart failure.[1]

References

  1. "CLEVIPREX (CLEVIDIPINE) EMULSION [THE MEDICINES COMPANY]". Retrieved 27 February 2014.

Template:Calcium channel blockers